论文部分内容阅读
目的:观察拉米夫定联合血浆置换治疗慢性乙型重型肝炎的疗效。方法:将48例慢性乙型重型肝炎患者随机分为对照组(22例),给予内科综合及血浆置换治疗;治疗组(26例),在此基础上加用拉米夫定,比较两组临床症状、TB(总胆红素)、PTA(凝血酶原活动度)、ALB及HBV-DNA含量。结果:治疗组在改善TB、PTA及提高治疗有效率、HBV-DNA阴转率方面较对照组差异有显著性(P<0.05)。结论:拉米夫定在血浆置换等的治疗基础上有可能进一步提高慢性乙型重型肝炎患者的治疗效果。
Objective: To observe the efficacy of lamivudine combined with plasma exchange in the treatment of chronic severe hepatitis B Methods: Forty-eight patients with chronic severe hepatitis B were randomly divided into control group (n = 22), treatment group (n = 26) and lamivudine plus lamivudine Clinical symptoms, TB (total bilirubin), PTA (prothrombin activity), ALB and HBV-DNA content. Results: The treatment group had significant difference (P <0.05) compared with the control group in improving the TB and PTA, improving the treatment efficiency and HBV-DNA negative conversion rate. Conclusion: Lamivudine may further improve the therapeutic effect of patients with chronic severe hepatitis B on the basis of plasma exchange.